OM Therapeutics
ML-enabled small molecule discovery marketplace for researchers.
Made possible by a technology stack that enables the empirical physical screening of billions of molecules against entire proteomes at the pico-scale, Om is building a small molecule discovery marketplace for researchers to easily pick their disease target of interest, select predicted molecular binders, and deliver selected molecules directly to their site — in a matter of weeks.
Marketplace product launch in Q4 2024 with 3,000 protein-small molecule datasets
75B total data points, and growing.
$250K initial deal with a top ML company.
Founding team members Devon, Adam, and Come each hold
PhDs in genetics, chemistry, and computer science with multiple patents in DNA barcoding methods, and experience across microarray and novel sequencing. CEO and Co-Founder, Devon, previously founded 1859 which raised $50m in VC funding to build AI models and microfluidic screening. Come and Adam also worked at 1859. Devon received his PhD in Chemical Biology from Scripps Research Institute, developing nucleic acid computation methodologies and programmable biomolecules.
